Alnylam Pharmaceuticals, Inc.

Analysis of ALNY Stock

Technical Perspective ALNY shows persistent weakness, with significant losses over recent months and deep drawdowns reflecting negative momentum. While the stock has stabilized above its yearly low, there are no clear technical signals indicating a strong reversal is imminent. The low beta suggests this decline is unusual for the stock, pointing to internal or sector-specific pressures rather than broader market trends.

Fundamental Assessment The company maintains robust revenue in the billion-dollar range and solid profitability, though margins have recently softened. Strong liquidity and cash reserves provide financial stability, but a low interest coverage ratio indicates some vulnerability to debt obligations. Operational returns are healthy, but asset efficiency remains low, which is typical for R&D-heavy biopharma firms.

Valuation & Risk Outlook Valuation multiples are exceptionally high, signaling that the stock is pricing in substantial future growth, yet negative earnings growth expectations raise concerns about sustainability. Risks are primarily company-specific, such as clinical outcomes or regulatory updates, rather than market-wide or sentiment-driven pressures. Despite low volatility historically, the stock remains susceptible to sharp declines based on news flow.

Investment Recommendation ALNY is not recommended for purchase at this time. The combination of weak technical momentum, lofty valuation multiples, and emerging margin pressures presents significant downside risk. While the company’s strong cash position and innovative pipeline offer long-term potential, investors should await clearer signs of operational improvement or a more compelling valuation entry point. Consider monitoring for future updates on pipeline progress or financial stabilization before committing capital.

RockFlow Model Forecast: Three Scenarios for 2026

Based on the provided analysis, here is a 12-month outlook for ALNY:

The primary catalysts for a potential rebound will be positive clinical or regulatory updates from its R&D pipeline, which could validate its high growth expectations and reverse the negative momentum. Key risks remain company-specific, including disappointing trial results, further margin erosion, or an inability to meet the lofty growth assumptions baked into its valuation. Given the absence of a clear technical reversal and the stock's high susceptibility to news-driven moves, the price is likely to remain volatile with a cautious bias; a re-test of recent lows is plausible unless a significant positive catalyst emerges, while a sustained rally above the $400 level would require a fundamental improvement in earnings outlook.

Wall Street Consensus

Most Wall Street analysts are optimistic about Alnylam Pharmaceuticals, Inc.'s 12-month outlook, with consensus target around $332.92, indicating expected upside potential.

Overall, ALNY has investment potential but also faces challenges. Here are key factors to weigh before investing.

ALNY has demonstrated substantial weakness across all measured timeframes, significantly underperforming the broader market. The stock has experienced a deep drawdown from its 52-week high but remains positioned well above its yearly low, indicating a pause in the downtrend without clear signs of a strong bullish reversal.

Over the past one and three months, ALNY has posted losses of 6.63% and 25.7%, respectively, showing accelerating negative momentum. This performance is substantially weaker than the market, as evidenced by its -31.33% relative strength over three months. The stock's low beta of 0.351 suggests this steep decline is somewhat anomalous and not typical of its usual lower volatility.

With a current price of $331.24, ALNY sits approximately 61% above its 52-week low but 33% below its high, placing it in the lower-middle portion of its yearly range. While still far from its lows, the significant 37.2% maximum drawdown suggests the stock remains technically weak and is not currently in an oversold condition that would suggest a strong rebound is imminent.

Revenue & Profitability ALNY demonstrates strong revenue performance with consistent billion-dollar quarterly figures, though Q4 2025 revenue of $1.10 billion declined from Q3's $1.25 billion. Profitability metrics remain solid with a 75.6% gross margin in Q4, though operating income ratio declined to 12.0% from 29.5% in Q3, indicating potential margin pressure from increased operating expenses. The net income ratio of 17.0% reflects effective bottom-line management despite the sequential decline.

Financial Health The company maintains excellent liquidity with a current ratio of 2.76 and quick ratio of 2.71, supported by substantial cash reserves of $21.99 per share. Debt management appears moderate with a debt ratio of 25.7%, though the interest coverage ratio of 1.02 suggests limited breathing room for interest obligations. Operating cash flow generation remains positive at $1.24 per share, supporting ongoing operations.

Operational Efficiency ALNY demonstrates strong shareholder returns with a robust ROE of 23.6%, indicating effective equity utilization. However, asset efficiency appears challenged with a low asset turnover of 0.22, typical for research-intensive biopharmaceutical companies. The 52.7-day cash conversion cycle reflects reasonable working capital management, though inventory turnover of 3.24 could potentially be optimized.

Valuation Level Analysis

ALNY's valuation metrics raise significant concerns, with exceptionally high multiples suggesting overvaluation. The trailing PE ratio of 156.12 and forward PE of 70.52 are extremely elevated, indicating investors are paying a substantial premium for current and near-term earnings. This is further supported by a staggering EV/EBITDA of 359.47 and a negative PEG ratio of -2.69, which reflects negative earnings growth expectations and reinforces that the stock appears overvalued based on its current financial performance.

Peer Comparison Analysis

Without specific industry average data, a precise peer comparison cannot be conducted. However, ALNY's metrics—particularly its PE ratios above 70 and PB ratio of 55.01—are almost certainly well above typical biotech or pharmaceutical industry averages. These extreme multiples suggest the market is pricing in significant future growth, but the negative PEG ratio indicates skepticism about achieving that growth, highlighting substantial valuation risks relative to the broader sector.

Volatility Risk ALNY demonstrates exceptionally low volatility risk relative to the broader market, as evidenced by its Beta of 0.351. However, its maximum drawdown of -37.2% over the past year highlights a significant potential for price depreciation despite its low correlation with market swings, indicating that company-specific news can drive substantial downside.

Other Risks The absence of short interest suggests that the market consensus is not betting against the stock, which can be interpreted positively. The primary risks are therefore more likely tied to company-specific factors such as clinical trial results, regulatory approvals, and the commercial success of its RNAi therapeutics, rather than negative sentiment or liquidity pressures.